<DOC>
	<DOC>NCT00004770</DOC>
	<brief_summary>OBJECTIVES: I. Assess the efficacy of thioctic acid in treating a single patient with mitochondrial myopathy.</brief_summary>
	<brief_title>Pilot Compassionate Use Study of Thioctic Acid Treatment in Mitochondrial Myopathy</brief_title>
	<detailed_description>PROTOCOL OUTLINE: The patient receives one thioctic acid tablet 3 times a day. If patient experiences no side effects after 1 week, 2 tablets are administered and given 3 times a day over 3 months for compassionate use. The patient is followed at weeks 3, 8, and 12.</detailed_description>
	<mesh_term>Muscular Diseases</mesh_term>
	<mesh_term>Mitochondrial Myopathies</mesh_term>
	<mesh_term>Thioctic Acid</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA: Disease Characteristics Long standing ophthalmoparesis and fatiguable weakness of the limbs Mild ataxia and no central nervous system involvement History of mitochondrial DNA deletion and a measurable biochemical defect of the respiratory chain Steady deterioration in skeletal muscle mass and power over 5 years Prior/Concurrent Therapy Previous participation in studies of muscle disease natural history (CRC Protocol 183A)</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2001</verification_date>
	<keyword>inborn errors of metabolism</keyword>
	<keyword>mitochondrial myopathy</keyword>
	<keyword>rare disease</keyword>
</DOC>